Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 11/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 11/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10007610 | 0.90 | GRIN2B (0.41) | MAOAMAOBGRIN1GRIN2BLMNA | |
| SCHEMBL10006926 | 0.88 | GAA (0.36) | MAOAMAOBTP53GRIN1GRIN2B | |
| SCHEMBL10006781 | 0.88 | TSPO (0.40) | MAOAMAOBALDH1A1 | |
| SCHEMBL10006747 | 0.87 | MAOA (0.42) | MAOAMAOBTP53LMNAMAPT | |
| SCHEMBL10006851 | 0.83 | TRPV1 (0.36) | MAOBTP53GRIN1GRIN2BLMNA | |
| SCHEMBL10006772 | 0.81 | MAOA (0.40) | MAOAMAOBGRIN1GRIN2BLMNA | |
| SCHEMBL10007454 | 0.81 | GABRG2 (0.38) | MAOBTP53LMNAMAPTHTR2C | |
| SCHEMBL10006847 | 0.77 | MEN1 (0.35) | GRIN1GRIN2BLMNAMAPTALDH1A1 | |
| SCHEMBL10007102 | 0.77 | ALDH1A1 (0.36) | TP53GRIN1GRIN2BMAPTALDH1A1 | |
| SCHEMBL10006794 | 0.76 | HTR2C (0.39) | MAOAMAOBGRIN1GRIN2BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2476682-B1 | 8-OXODIHYDROPURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-04-26 | — | — | EP | disclosed |
| US-8735406-B2 | 8-oxodihydropurine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2476682-A1 | 8-OXODIHYDROPURINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | FAAH, FAAH2, TPMT | MAOA 17/4885MAOB 15/4885TP53 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.